Nutritional supplements that may be helpful: People with CF
tend to have insufficient pancreas
function. Supplementation with pancreatic enzymes will
often lead to improved digestion, especially of
fats. The current recommendation for people with cystic fibrosis is to supplement with
pancreatic enzymes at meals. Amounts should not exceed 10,000 IU of lipase per day per 2.2 pounds body weight4 or 500 to 1,000
lipase units per gram of dietary fat consumed,5 as larger amounts may damage the
large intestine. A double-blind trial found enteric-coated microsphere enzyme preparations to
be superior to enteric-coated capsules for reduction of abdominal pain and improvement of
digestion.6 Because pancreatin is rapidly emptied from the stomach during
digestion, people taking these enzymes may obtain better results by spreading supplementation
throughout the meal.7
Taurine is an amino
acid and a component of bile acids, which are important for proper fat digestion.
Some,8 9 but not all,10 investigators have reported
improvement in fat digestion among people with CF when they supplemented with 30 mg taurine
per 2.2 pounds of body weight daily. Greater improvement was seen in people with the worst
maldigestion.11
The impaired digestion of fats in people with CF often leads to a deficiency of essential
fatty acids. This deficiency may in turn lead to lowered immune function, which makes people with CF more
susceptible to respiratory infection.12 This deficiency may be reversed by
supplementation with corn oil (1 gram per
2.2 pounds body weight per day),13 safflower oil (1 gram per 2.2 pounds body weight
per day),14 linoleic acid (7.7 grams per day),15 and eicosapentaenoic
acid (EPA from fish oil) (2.7 grams per day).16
EPA supplementation was particularly effective. In a double-blind trial, six weeks of
supplementation with 2.7 grams of EPA per day led to a reduction in sputum and improvement in
lung function in children with chronic respiratory infection due to CF.17
The fat malabsorption associated with CF often leads to a deficiency of fat-soluble
vitamins. Oral supplementation of these nutrients is considered crucial to maintaining good
nutritional status.18 Current recommendations for supplementation are as follows:
vitamin A, 5,000 to 10,000 IU/day; vitamin D, 1,000 to 2,000 IU/day;
vitamin E, 100 to 300 IU/day; and vitamin K, 5 mg
every three days. Of the water-soluble vitamins, only
vitamin B12 is poorly absorbed in cystic fibrosis,19 and taking pancreatic
enzymes helps prevent B12 deficiencies.20
The malabsorption produced by CF may adversely affect mineral absorption as well. Blood
concentrations of zinc were low in a group of children with
CF.21 One child with CF was reported to have a severe generalized dermatitis that
resolved upon correction of zinc and fatty acid deficiencies by using a formula containing
zinc (about 3 mg per day) and medium chain
triglycerides (amount not reported).22
Children with slowed growth associated with CF were found, in a preliminary study, to have
overgrowth of bacteria in the small intestine compared to healthy children.23 There
is as yet no evidence that elimination of this overgrowth will lead to improvement of CF
symptoms.
Are there any side effects or interactions? Refer to the individual supplement for
information about any side effects or interactions.
References:
1. Wilson DC, Pencharz PB. Nutrition and cystic fibrosis.
Nutrition 1998;14:792–5 [review].
2. Turck D, Michaud L. Cystic fibrosis: nutritional consequences and
management. Baillieres Clin Gastroenterol 1998;12:805–22 [review].
3. Schneiderman-Walker J, Pollock SL, Corey M, et al. A randomized
controlled trial of a 3-year home exercise program in cystic fibrosis. J Pediatr
2000;136:304–10.
4. Littlewood JM, Wolfe SP. Control of malabsorption in cystic fibrosis.
Paediatr Drugs 2000;2:205–22.
5. Borowitz DS, Grand RJ, Durie PR. Use of pancreatic enzyme supplements
for patients with cystic fibrosis in the context of fibrosing colonopathy. Consensus
committee. J Pediatr 1995;127:681–4.
6. Vyas H, Matthew DJ, Milla PJ. A comparison of enteric coated
microspheres with enteric coated tablet pancreatic enzyme preparations in cystic fibrosis. A
controlled study. Eur J Pediatr 1990;149:241–3.
7. Taylor CJ, Hillel PG, Ghosal S, et al. Gastric emptying and intestinal
transit of pancreatic enzyme supplements in cystic fibrosis. Arch Dis Child
1999;80:149–52.
8. Darling PB, Lepage G, Leroy C, et al. Effect of taurine supplements on
fat absorption in cystic fibrosis. Pediatr Res 1985;19:578–82.
9. Belli DC, Levy E, Darling PB, et al. Taurine improves the absorption
of a fat meal in patients with cystic fibrosis. Pediatrics 1987;80:517–23.
10. Thompson GN, Robb TA, Davidson GP. Taurine supplementation, fat
absorption, and growth in cystic fibrosis. J Pediatr 1987;111:501–6.
11. Darling PB, Lepage G, Leroy C, et al. Effect of taurine supplements
on fat absorption in cystic fibrosis. Pediatr Res 1985;19:578–82.
12. Chase HP, Dupont J. Abnormal levels of prostaglandins and fatty acids
in blood of children with cystic fibrosis. Lancet 1978;2:236–8.
13. Rosenlund ML, Selekman JA, Kim HK, Kritchevsky D. Dietary essential
fatty acids in cystic fibrosis. Pediatrics 1977;59:428–32.
14. Lloyd-Still JD, Simon SH, Wessel HU, Gibson LE. Intravenous linoleic
acid supplementation in children with cystic fibrosis. Pediatrics
1979;64:50–2.
15. Chase HP, Dupont J. Abnormal levels of prostaglandins and fatty acids
in blood of children with cystic fibrosis. Lancet 1978;2:236–8.
16. Lawrence R, Sorrell T. Eicosapentaenoic acid in cystic fibrosis:
evidence of a pathogenic role for leukotriene B4. Lancet 1993;342:465–9.
17. Lawrence R, Sorrell T. Eicosapentaenoic acid in cystic fibrosis:
evidence of a pathogenic role for leukotriene B4. Lancet 1993;342:465–9.
18. Turck D, Michaud L. Cystic fibrosis: nutritional consequences and
management. Baillieres Clin Gastroenterol 1998;12:805–22 [review].
19. Lindemans J, Neijens HJ, Kerrebijn KF, Abels J. Vitamin B12
absorption in cystic fibrosis. Acta Paediatr Scand 1984;73:537–40.
20. Gueant JL, Vidailhet M, Pasquet C, et al. Effect of pancreatic
extracts on the faecal excretion and on the serum concentration of cobalamin and cobalamin
analogues in cystic fibrosis. Clin Chim Acta 1984;137:33–41.
21. Krebs NF, Sontag M, Accurso FJ, Hambidge KM. Low plasma zinc
concentrations in young infants with cystic fibrosis. J Pediatr
1998;133:761–4.
22. Hansen RC, Lemen R, Revsin B. Cystic fibrosis manifesting with
acrodermatitis enteropathica-like eruption. Arch Dermatol 1983;119:51–5.
23. Berezin S, Dhole A, Mascia A, Newman LJ. Small intestinal bacterial
overgrowth may impair the nutritional stature of children with cystic fibrosis. Fed
Proc 1985;44:1858 [abstract].